CP 50,556-1 / LEVONANTRADOL synthetic, CB1 & CB2 agonist

 

Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting.                                                                            (abst – 1981)  http://www.ncbi.nlm.nih.gov/pubmed/7298877

 

Randomised Clinical Trial of Levonantradol and Chlorpromazine in the Prevention of Radiotherapy-induced Vomiting.                                                         (abst – 1982)  http://www.ncbi.nlm.nih.gov/pubmed/6754212

 

Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.                                                            (abst – 1982)  http://www.ncbi.nlm.nih.gov/pubmed/7139853

 

 

 

 

 

 

 

 

Respiratory and cardiovascular depressant effects of nabilone, N-methyllevonantradol and delta 9-tetrahydrocannabinol in anesthetized cats.                                         (abst – 1983)  http://jpet.aspetjournals.org/content/227/2/508.abstract?maxtoshow=&hits=80&RESU       LTFORMAT=&fullt   ext=marihuana&searchid=1&FIRSTINDEX=1920&resourcetype=HWCIT

 

Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy.                                                         (abst – 1983)  http://www.ncbi.nlm.nih.gov/pubmed/6309451

 

Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.                                                                     (abst – 1985)  http://www.ncbi.nlm.nih.gov/pubmed/2981616

 

Thujone exhibits low affinity for cannabinoid receptors but fails to evoke cannabimimetic responses.       (abst – 1999)                           http://www.ncbi.nlm.nih.gov/pubmed/10080239

 

Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.                                                         (full – 2001)  http://www.nature.com/npp/journal/v24/n2/full/1395605a.html

 

Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse? (full – 2011)                                      http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139381/?tool=pubmed

 

Share a link for